

# Marja-Riitta Taskinen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5377028/publications.pdf>

Version: 2024-02-01

475  
papers

59,061  
citations

2101

100  
h-index

1158

229  
g-index

504  
all docs

504  
docs citations

504  
times ranked

44158  
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	2.2	4,871
2	Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. <i>Diabetes Care</i> , 2001, 24, 683-689.	8.6	4,086
3	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	2.2	2,767
4	Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels. <i>Science</i> , 2007, 316, 1331-1336.	12.6	2,623
5	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
6	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	2.2	2,132
7	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.8	1,753
8	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	2.2	1,392
9	Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. <i>Nature Genetics</i> , 2008, 40, 189-197.	21.4	1,286
10	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	2.2	993
11	Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. <i>Lancet</i> , The, 2007, 370, 1687-1697.	13.7	918
12	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	2.2	835
13	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
14	Diabetic dyslipidaemia: from basic research to clinical practice*. <i>Diabetologia</i> , 2003, 46, 733-749.	6.3	717
15	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	2.2	644
16	Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1225-1236.	2.4	639
17	Overproduction of large VLDL particles is driven by increased liver fat content in man. <i>Diabetologia</i> , 2006, 49, 755-765.	6.3	570
18	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 3-46.	0.8	561

#	ARTICLE	IF	CITATIONS
19	Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome. <i>Diabetes Care</i> , 2009, 32, 493-498.	8.6	488
20	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 655-666.	11.4	473
21	Metabolic Syndrome in Type 1 Diabetes. <i>Diabetes Care</i> , 2005, 28, 2019-2024.	8.6	360
22	One-Year Treatment With Exenatide Improves $\beta$ -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2009, 32, 762-768.	8.6	354
23	Lipoprotein lipase activity in adipose tissue and skeletal muscle of runners: Relation to serum lipoproteins. <i>Metabolism: Clinical and Experimental</i> , 1978, 27, 1661-1671.	3.4	352
24	Metabolic Consequences of a Family History of NIDDM (The Botnia Study): Evidence for Sex-Specific Parental Effects. <i>Diabetes</i> , 1996, 45, 1585-1593.	0.6	342
25	Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol. <i>Circulation</i> , 1997, 96, 2137-2143.	1.6	338
26	Comparison of Insulin Regimens in Patients with Non-Insulin-Dependent Diabetes Mellitus. <i>New England Journal of Medicine</i> , 1992, 327, 1426-1433.	27.0	330
27	An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. <i>Cell Metabolism</i> , 2018, 27, 559-571.e5.	16.2	321
28	Predictors of and Longitudinal Changes in Insulin Sensitivity and Secretion Preceding Onset of Type 2 Diabetes. <i>Diabetes</i> , 2005, 54, 166-174.	0.6	315
29	New insights into the pathophysiology of dyslipidemia in type 2 diabetes. <i>Atherosclerosis</i> , 2015, 239, 483-495.	0.8	314
30	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies – a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	2.2	303
31	Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. <i>Diabetologia</i> , 2006, 49, 2049-2057.	6.3	302
32	Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). <i>Nature Genetics</i> , 2004, 36, 371-376.	21.4	295
33	Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. <i>Diabetologia</i> , 1997, 40, 454-462.	6.3	285
34	Changes in serum lipoprotein pattern induced by acute infections. <i>Metabolism: Clinical and Experimental</i> , 1988, 37, 859-865.	3.4	270
35	PPAR $\alpha$ gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2015, 63, 164-173.	3.7	270
36	Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 65-74.	4.4	266

#	ARTICLE	IF	CITATIONS
37	Common Missense Variant in the Glucokinase Regulatory Protein Gene Is Associated With Increased Plasma Triglyceride and C-Reactive Protein but Lower Fasting Glucose Concentrations. <i>Diabetes</i> , 2008, 57, 3112-3121.	0.6	264
38	Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease. <i>Circulation</i> , 2003, 107, 1733-1737.	1.6	263
39	Effects of Oral and Transdermal Estrogen Replacement Therapy on Markers of Coagulation, Fibrinolysis, Inflammation and Serum Lipids and Lipoproteins in Postmenopausal Women. <i>Thrombosis and Haemostasis</i> , 2001, 85, 619-625.	3.4	242
40	Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. <i>Nature Genetics</i> , 1998, 18, 369-373.	21.4	241
41	Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. <i>Atherosclerosis</i> , 2003, 166, 387-394.	0.8	235
42	Overproduction of VLDL 1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1697-1703.	2.4	235
43	Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. <i>Journal of Hepatology</i> , 2012, 57, 1276-1282.	3.7	232
44	Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). <i>American Journal of Kidney Diseases</i> , 2005, 45, 485-493.	1.9	231
45	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial. <i>International Journal of Cardiology</i> , 2014, 176, 55-61.	1.7	229
46	Relation of plasma high-density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of man. <i>Atherosclerosis</i> , 1978, 29, 497-501.	0.8	224
47	Effects of Exenatide on Measures of $\beta$ -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 2041-2047.	8.6	221
48	Lipoprotein lipase in diabetes. <i>Diabetes/metabolism Reviews</i> , 1987, 3, 551-570.	0.3	214
49	The metabolic syndrome influences the risk of chronic complications in patients with Type II diabetes. <i>Diabetologia</i> , 2001, 44, 1148-1154.	6.3	213
50	Heritability and familiarity of type 2 diabetes and related quantitative traits in the Botnia Study. <i>Diabetologia</i> , 2011, 54, 2811-2819.	6.3	202
51	Impaired Responsiveness to NO in Newly Diagnosed Patients With Rheumatoid Arthritis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1637-1641.	2.4	198
52	Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. <i>Lancet</i> , The, 1997, 350, S20-S23.	13.7	187
53	Ectopic lipid storage and insulin resistance: a harmful relationship. <i>Journal of Internal Medicine</i> , 2013, 274, 25-40.	6.0	183
54	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1-44.	0.8	180

#	ARTICLE	IF	CITATIONS
55	Novel Loci for Metabolic Networks and Multi-Tissue Expression Studies Reveal Genes for Atherosclerosis. <i>PLoS Genetics</i> , 2012, 8, e1002907.	3.5	171
56	Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. <i>Diabetologia</i> , 2009, 52, 684-690.	6.3	169
57	Metabolic Basis of Hypotriglyceridemic Effects of Insulin in Normal Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1454-1464.	2.4	167
58	Diabetic dyslipidemia. <i>Atherosclerosis Supplements</i> , 2002, 3, 47-51.	1.2	166
59	Intense physical training decreases circulating antioxidants and endothelium-dependent vasodilatation in vivo. <i>Atherosclerosis</i> , 1999, 145, 341-349.	0.8	159
60	Effects of NIDDM on Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B Metabolism: Studies Before and After Sulfonylurea Therapy. <i>Diabetes</i> , 1986, 35, 1268-1277.	0.6	157
61	Postprandial hypertriglyceridemia as a coronary risk factor. <i>Clinica Chimica Acta</i> , 2014, 431, 131-142.	1.1	157
62	Niacin Cures Systemic NAD <sup>+</sup> Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy. <i>Cell Metabolism</i> , 2020, 31, 1078-1090.e5.	16.2	154
63	Dietary Fructose and the Metabolic Syndrome. <i>Nutrients</i> , 2019, 11, 1987.	4.1	152
64	High density lipoprotein subfractions and postheparin plasma lipases in alcoholic men before and after ethanol withdrawal. <i>Metabolism: Clinical and Experimental</i> , 1982, 31, 1168-1174.	3.4	150
65	Personal model-assisted identification of NAD <sup>+</sup> and $\gamma$ -glutathione metabolism as intervention target in NAFLD. <i>Molecular Systems Biology</i> , 2017, 13, 916.	7.2	147
66	Diabetic dyslipidaemia. <i>Current Opinion in Lipidology</i> , 2006, 17, 238-246.	2.7	143
67	The insulin resistance syndrome and postprandial lipid intolerance in smokers. <i>Atherosclerosis</i> , 1997, 129, 79-88.	0.8	140
68	Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition. <i>Diabetes Care</i> , 2010, 33, 1734-1737.	8.6	139
69	Genomewide Scan for Familial Combined Hyperlipidemia Genes in Finnish Families, Suggesting Multiple Susceptibility Loci Influencing Triglyceride, Cholesterol, and Apolipoprotein B Levels. <i>American Journal of Human Genetics</i> , 1999, 64, 1453-1463.	6.2	137
70	Circulating Adiponectin Levels Are Reduced in Nonobese but Insulin-Resistant First-Degree Relatives of Type 2 Diabetic Patients. <i>Diabetes</i> , 2003, 52, 1182-1186.	0.6	137
71	Peroxisome Proliferator-Activated Receptor $\alpha$ Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease. <i>Circulation</i> , 2002, 105, 1440-1445.	1.6	136
72	High density lipoprotein subfractions in relation to lipoprotein lipase activity of tissues in man—evidence for reciprocal regulation of HDL2 and HDL3 levels by lipoprotein lipase. <i>Clinica Chimica Acta</i> , 1981, 112, 325-332.	1.1	135

#	ARTICLE	IF	CITATIONS
73	Smoking cessation improves insulin sensitivity in healthy middle-aged men. <i>European Journal of Clinical Investigation</i> , 1997, 27, 450-456.	3.4	133
74	Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2144-2150.	2.4	133
75	Effect of Obesity on the Response to Insulin Therapy in Noninsulin-Dependent Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 4037-4043.	3.6	132
76	Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. <i>Atherosclerosis</i> , 1999, 147, 133-138.	0.8	131
77	Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 513-519.	2.4	129
78	Quantitative and Qualitative Lipoprotein Abnormalities in Diabetes Mellitus. <i>Diabetes</i> , 1992, 41, 12-17.	0.6	123
79	Causes and Consequences of Hypertriglyceridemia. <i>Frontiers in Endocrinology</i> , 2020, 11, 252.	3.5	122
80	Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. <i>Atherosclerosis</i> , 2000, 150, 167-177.	0.8	121
81	Endothelial Dysfunction in Men With Small LDL Particles. <i>Circulation</i> , 2000, 102, 716-721.	1.6	120
82	Genetic architecture of human plasma lipidome and its link to cardiovascular disease. <i>Nature Communications</i> , 2019, 10, 4329.	12.8	120
83	Postprandial Hypertriglyceridemia and Insulin Resistance in Normoglycemic First-Degree Relatives of Patients with Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 1999, 131, 27.	3.9	118
84	One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress. <i>Atherosclerosis</i> , 2010, 212, 223-229.	0.8	118
85	Long-term Use of Nicotine Gum Is Associated With Hyperinsulinemia and Insulin Resistance. <i>Circulation</i> , 1996, 94, 878-881.	1.6	117
86	ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan. <i>Diabetes</i> , 2009, 58, 2018-2026.	0.6	116
87	Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. <i>Journal of Medical Genetics</i> , 2013, 50, 298-308.	3.2	116
88	Fatty liver, insulin resistance, and dyslipidemia. <i>Current Diabetes Reports</i> , 2008, 8, 60-64.	4.2	115
89	What does postprandial hyperglycaemia mean?. <i>Diabetic Medicine</i> , 2004, 21, 208-213.	2.3	114
90	Effects of a Mediterranean-inspired diet on blood lipids, vascular function and oxidative stress in healthy subjects. <i>Clinical Science</i> , 2004, 106, 519-525.	4.3	114

#	ARTICLE	IF	CITATIONS
91	Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B-Containing Lipoproteins in NIDDM. <i>Diabetes</i> , 1990, 39, 1017-1027.	0.6	112
92	An Immune Response Network Associated with Blood Lipid Levels. <i>PLoS Genetics</i> , 2010, 6, e1001113.	3.5	112
93	Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. <i>Journal of Lipid Research</i> , 2010, 51, 2341-2351.	4.2	111
94	Plasma Lipoproteins, Lipolytic Enzymes, and Very Low Density Lipoprotein Triglyceride Turnover in Cushing's Syndrome*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983, 57, 619-626.	3.6	109
95	Alcohol-induced changes in serum lipoproteins and in their metabolism. <i>American Heart Journal</i> , 1987, 113, 458-464.	2.7	109
96	Insulin resistance and lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 1995, 6, 153-160.	2.7	108
97	A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. <i>FASEB Journal</i> , 2003, 17, 1434-1440.	0.5	108
98	A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. <i>Journal of Lipid Research</i> , 2005, 46, 58-67.	4.2	108
99	Differential Effects of Oral and Transdermal Estrogen Replacement Therapy on Endothelial Function in Postmenopausal Women. <i>Circulation</i> , 2000, 102, 2687-2693.	1.6	107
100	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\pm$ ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	104
101	Increased Resting Metabolic Rates in Obese Subjects with Non-insulin-dependent Diabetes Mellitus and the Effect of Sulfonyleurea Therapy. <i>Diabetes</i> , 1986, 35, 1-5.	0.6	103
102	APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease. <i>Journal of Lipid Research</i> , 2004, 45, 750-756.	4.2	103
103	Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. <i>Atherosclerosis</i> , 1996, 127, 245-253.	0.8	101
104	Plasma high-density lipoprotein concentration and subfraction distribution in relation to triglyceride metabolism. <i>American Heart Journal</i> , 1987, 113, 543-548.	2.7	100
105	Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. <i>European Journal of Endocrinology</i> , 2009, 161, 715-722.	3.7	100
106	Interrelationships Among Insulin's Antilipolytic and Glucoregulatory Effects and Plasma Triglycerides in Nondiabetic and Diabetic Patients With Endogenous Hypertriglyceridemia. <i>Diabetes</i> , 1988, 37, 1271-1278.	0.6	98
107	In Vivo Low Density Lipoprotein Oxidation Relates to Coronary Reactivity in Young Men. <i>Journal of the American College of Cardiology</i> , 1997, 30, 97-102.	2.8	98
108	Coronary Flow Reserve in Young Men With Familial Combined Hyperlipidemia. <i>Circulation</i> , 1999, 99, 1678-1684.	1.6	98

#	ARTICLE	IF	CITATIONS
109	Cardiac Steatosis Associates With Visceral Obesity in Nondiabetic Obese Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1189-1197.	3.6	98
110	Cross-species analyses implicate Lipin 1 involvement in human glucose metabolism. <i>Human Molecular Genetics</i> , 2006, 15, 377-386.	2.9	97
111	The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. <i>Atherosclerosis</i> , 1998, 139, 49-56.	0.8	96
112	3 Hyperlipidaemia in diabetes. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1990, 4, 743-775.	1.0	95
113	Type 2 Diabetes as a Lipid Disorder. <i>Current Molecular Medicine</i> , 2005, 5, 297-308.	1.3	94
114	PPAR $\alpha$ : an emerging therapeutic target in diabetic microvascular damage. <i>Nature Reviews Endocrinology</i> , 2010, 6, 454-463.	9.6	92
115	A micromethod for assay of lipoprotein lipase activity in needle biopsy samples of human adipose tissue and skeletal muscle. <i>Clinica Chimica Acta</i> , 1980, 104, 107-117.	1.1	91
116	Genome Scans Provide Evidence for Low-HDL-C Loci on Chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish Families. <i>American Journal of Human Genetics</i> , 2002, 70, 1333-1340.	6.2	91
117	Combined Analysis of Genome Scans of Dutch and Finnish Families Reveals a Susceptibility Locus for High-Density Lipoprotein Cholesterol on Chromosome 16q. <i>American Journal of Human Genetics</i> , 2003, 72, 903-917.	6.2	89
118	Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. <i>Human Molecular Genetics</i> , 2012, 21, 1444-1455.	2.9	89
119	Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. <i>Journal of Internal Medicine</i> , 2017, 282, 187-201.	6.0	89
120	Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor. <i>Molecular and Cellular Biology</i> , 2005, 25, 1537-1548.	2.3	88
121	Statins are diabetogenic – Myth or reality?. <i>Atherosclerosis Supplements</i> , 2012, 13, 1-10.	1.2	88
122	Lipid intolerance in smokers. <i>Journal of Internal Medicine</i> , 1995, 237, 449-455.	6.0	87
123	Sequence of alcohol-induced initial changes in plasma lipoproteins (VLDL and HDL) and lipolytic enzymes in humans. <i>Metabolism: Clinical and Experimental</i> , 1985, 34, 112-119.	3.4	86
124	Circulating Oxidized Low-Density Lipoprotein and Its Association With Carotid Intima-Media Thickness in Asymptomatic Members of Familial Combined Hyperlipidemia Families. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1492-1497.	2.4	86
125	Cardiac steatosis and left ventricular function in men with metabolic syndrome. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, 103.	3.3	86
126	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. , 2005, 4, 13.		84



#	ARTICLE	IF	CITATIONS
127	Effect of Acute Elevation of Plasma Glycerol, Triglyceride and FFA Levels on Glucose Utilization and Plasma Insulin. <i>Diabetes</i> , 1968, 17, 76-82.	0.6	83
128	Ectopic Fat Depots and Left Ventricular Function in Nondiabetic Men With Nonalcoholic Fatty Liver Disease. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	2.6	83
129	The dual glucoseâ€dependent insulinotropic peptide and glucagonâ€like peptideâ€1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2451-2459.	4.4	83
130	Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 374-377.	4.4	82
131	Amerindian-specific regions under positive selection harbour new lipid variants in Latinos. <i>Nature Communications</i> , 2014, 5, 3983.	12.8	81
132	The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. <i>Frontiers in Endocrinology</i> , 2020, 11, 474.	3.5	81
133	Lipoproteins, Lipolytic Enzymes, and Hormonal Status in Hypothyroid Women at Different Levels of Substitution*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 66, 51-56.	3.6	80
134	The effect of moderate alcohol intake on serum apolipoprotein A-I-containing lipoproteins and lipoprotein (a). <i>Metabolism: Clinical and Experimental</i> , 1991, 40, 1168-1172.	3.4	80
135	Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. <i>Diabetologia</i> , 2012, 55, 915-925.	6.3	80
136	Effects of caloric restriction on lipid metabolism in man changes of tissue lipoprotein lipase activities and of serum lipoproteins. <i>Atherosclerosis</i> , 1979, 32, 289-299.	0.8	79
137	Comparison of the effects of two different doses of alcohol on serum lipoproteins, HDL-subfractions and apolipoproteins A-I and A-II: a controlled study. <i>European Journal of Clinical Investigation</i> , 1988, 18, 472-480.	3.4	79
138	I and c/g polymorphisms of the apolipoprotein B gene locus are associated with serum cholesterol and LDL-cholesterol levels in Finland. <i>Atherosclerosis</i> , 1988, 74, 47-54.	0.8	79
139	Ethanol-induced Alterations of Glucose Tolerance, Postglucose Hypoglycemia, and Insulin Secretion in Normal, Obese, and Diabetic Subjects. <i>Diabetes</i> , 1975, 24, 933-943.	0.6	78
140	Short-term effects of moderate alcohol consumption on lipid metabolism and energy balance in normal men. <i>Metabolism: Clinical and Experimental</i> , 1989, 38, 166-171.	3.4	78
141	Effects of Gemfibrozil on Low-Density Lipoprotein Particle Size, Density Distribution, and Composition in Patients With Type II Diabetes. <i>Diabetes Care</i> , 1993, 16, 584-592.	8.6	78
142	USF1 and dyslipidemias: converging evidence for a functional intronic variant. <i>Human Molecular Genetics</i> , 2005, 14, 2595-2605.	2.9	78
143	Association of Carotid Intima-Media Thickness With Angiographic Severity and Extent of Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2006, 97, 624-629.	1.6	78
144	The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. <i>Diabetologia</i> , 2015, 58, 464-473.	6.3	78

#	ARTICLE	IF	CITATIONS
145	Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 84-94.	4.4	78
146	Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2429-2435.	2.8	77
147	Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. <i>American Journal of Cardiology</i> , 2000, 86, 1080-1085.	1.6	75
148	Differing Associations of Lipid and Lipoprotein Disturbances With the Macrovascular and Microvascular Complications of Type 1 Diabetes. <i>Diabetes Care</i> , 2001, 24, 2071-2077.	8.6	74
149	Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity. <i>Journal of Lipid Research</i> , 2009, 50, 183-192.	4.2	74
150	Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy. <i>Diabetes Care</i> , 2010, 33, 215-220.	8.6	74
151	Effects of Endogenous Sex Steroids on Serum Lipoproteins and Postheparin Plasma Lipolytic Enzymes*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 66, 408-413.	3.6	72
152	Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol. <i>Circulation</i> , 1998, 98, 1993-1999.	1.6	72
153	Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. <i>Diabetologia</i> , 2005, 48, 1207-1215.	6.3	72
154	Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD. <i>Current Atherosclerosis Reports</i> , 2019, 21, 27.	4.8	72
155	Serum Lipids and the Progression of Nephropathy in Type 1 Diabetes. <i>Diabetes Care</i> , 2006, 29, 317-322.	8.6	71
156	A family history of diabetes is associated with reduced physical fitness in the Prevalence, Prediction and Prevention of Diabetes (PPP)-Botnia study. <i>Diabetologia</i> , 2010, 53, 1709-1713.	6.3	71
157	Lipoprotein lipase of adipose tissue and skeletal muscle in human obesity: Response to glucose and to semistarvation. <i>Metabolism: Clinical and Experimental</i> , 1981, 30, 810-817.	3.4	70
158	G-250A Substitution in Promoter of Hepatic Lipase Gene Is Associated With Dyslipidemia and Insulin Resistance in Healthy Control Subjects and in Members of Families With Familial Combined Hyperlipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1789-1795.	2.4	70
159	Postprandial Lipemia Associates with Liver Fat Content. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3052-3059.	3.6	70
160	Progression of Atherosclerosis Is Associated With Variation in the $\epsilon$ 1-Antitrypsin Gene. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 644-649.	2.4	69
161	Decreased High-Density Lipoprotein (HDL) Particle Size, $\text{Pre}\beta_2$ , and Large HDL Subspecies Concentration in Finnish Low-HDL Families. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 897-902.	2.4	69
162	Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. <i>Diabetologia</i> , 2010, 53, 1846-1855.	6.3	67

#	ARTICLE	IF	CITATIONS
163	Diabetes as a case study of chronic disease management with a personalized approach: The role of a structured feedback loop. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, 5-10.	2.8	67
164	7 Enzymes involved in triglyceride hydrolysis. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1987, 1, 639-666.	1.0	66
165	Bedtime Insulin for Suppression of Overnight Free Fatty Acid, Blood Glucose, and Glucose Production in NIDDM. <i>Diabetes</i> , 1989, 38, 580-588.	0.6	66
166	Normalization of Lipoprotein Composition by Intraperitoneal Insulin in IDDM: Role of increased hepatic lipase activity. <i>Diabetes Care</i> , 1994, 17, 6-12.	8.6	66
167	Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. <i>Journal of Internal Medicine</i> , 2004, 256, 119-127.	6.0	66
168	Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2190-2197.	2.8	66
169	Metabolic Consequences of Sustained Suppression of Free Fatty Acids by Acipimox in Patients With NIDDM. <i>Diabetes</i> , 1993, 42, 1559-1566.	0.6	65
170	Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. <i>Diabetologia</i> , 2009, 52, 2522-2530.	6.3	65
171	The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. <i>Diabetologia</i> , 2006, 49, 527-537.	6.3	64
172	Paradoxical Dissociation Between Hepatic Fat Content and De Novo Lipogenesis Due to PNPLA3 Sequence Variant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E821-E825.	3.6	64
173	GLUCOSE TOLERANCE AND PLASMA INSULIN IN MAN DURING ACUTE AND CHRONIC ADMINISTRATION OF NICOTINIC ACID. <i>Acta Medica Scandinavica</i> , 1969, 186, 247-253.	0.0	63
174	Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. <i>Nature Communications</i> , 2020, 11, 1891.	12.8	63
175	Relationship of Phospholipid Transfer Protein Activity to HDL and Apolipoprotein B-Containing Lipoproteins in Subjects With and Without Type 1 Diabetes. <i>Diabetes</i> , 2002, 51, 3300-3305.	0.6	63
176	Accelerated turnover of very low density lipoprotein triglycerides in chronic alcohol users. <i>Atherosclerosis</i> , 1984, 53, 185-193.	0.8	62
177	Use of Genome-Wide Expression Data to Mine the "Gray Zone" of GWA Studies Leads to Novel Candidate Obesity Genes. <i>PLoS Genetics</i> , 2010, 6, e1000976.	3.5	62
178	Long-TE <sup>1</sup> H MRS suggests that liver fat is more saturated than subcutaneous and visceral fat. <i>NMR in Biomedicine</i> , 2011, 24, 238-245.	2.8	62
179	Quantitative Comparison of Angiographic Characteristics of Coronary Artery Disease in Patients With Noninsulin-Dependent Diabetes Mellitus Compared With Matched Nondiabetic Control Subjects. <i>American Journal of Cardiology</i> , 1997, 80, 550-556.	1.6	60
180	Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. <i>Atherosclerosis</i> , 1998, 139, 77-82.	0.8	60

#	ARTICLE	IF	CITATIONS
181	Common Hepatic Nuclear Factor-4 Variants Are Associated With High Serum Lipid Levels and the Metabolic Syndrome. <i>Diabetes</i> , 2006, 55, 1970-1977.	0.6	60
182	Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?. <i>Current Atherosclerosis Reports</i> , 2016, 18, 59.	4.8	60
183	Kinetics of plasma triglycerides in abdominal obesity. <i>Current Opinion in Lipidology</i> , 2017, 28, 11-18.	2.7	60
184	Polygenic Hyperlipidemias and Coronary Artery Disease Risk. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002725.	3.6	60
185	Hormone Replacement Therapy Lowers Plasma Lp(a) Concentrations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 1215-1221.	2.4	60
186	Polymorphisms of the gene encoding cholesterol ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease. <i>Human Genetics</i> , 1991, 87, 574-8.	3.8	59
187	Postprandial lipid metabolism in diabetes. <i>Atherosclerosis</i> , 1998, 141, S53-S55.	0.8	59
188	Association Between Carotid Intima-Media Thickness and Low-Density Lipoprotein Size and Susceptibility of Low-Density Lipoprotein to Oxidation in Asymptomatic Members of Familial Combined Hyperlipidemia Families. <i>Stroke</i> , 2002, 33, 1255-1260.	2.0	59
189	Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 950-955.	2.4	59
190	Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. <i>Obesity Reviews</i> , 2019, 20, 599-611.	6.5	59
191	Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. <i>Nature Reviews Cardiology</i> , 2022, 19, 577-592.	13.7	59
192	Postprandial Elevation of ApoB-48-Containing Triglyceride-Rich Particles and Retinyl Esters in Normolipemic Males Who Smoke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2096-2102.	2.4	58
193	Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2218-2224.	2.4	58
194	USF1 deficiency activates brown adipose tissue and improves cardiometabolic health. <i>Science Translational Medicine</i> , 2016, 8, 323ra13.	12.4	58
195	A gene variant of <i>PNPLA3</i> , but not of <i>APOC3</i> , is associated with histological parameters of NAFLD in an obese population. <i>Obesity</i> , 2013, 21, 2138-2145.	3.0	57
196	Multiple Lipoprotein Abnormalities in Type I Diabetic Patients With Renal Disease. <i>Diabetes</i> , 1996, 45, 974-979.	0.6	56
197	HDLs Containing Apolipoproteins A-I and A-II (LpA-I:A-II) as Markers of Coronary Artery Disease in Men With Non-Insulin-Dependent Diabetes Mellitus. <i>Circulation</i> , 1995, 92, 364-370.	1.6	55
198	Phenotype expression in familial combined hyperlipidemia. <i>Atherosclerosis</i> , 1997, 133, 245-253.	0.8	54

#	ARTICLE	IF	CITATIONS
199	WW-Domain-Containing Oxidoreductase Is Associated with Low Plasma HDL-C Levels. <i>American Journal of Human Genetics</i> , 2008, 83, 180-192.	6.2	54
200	Deep subcutaneous adipose tissue is more saturated than superficial subcutaneous adipose tissue. <i>International Journal of Obesity</i> , 2013, 37, 620-622.	3.4	53
201	Novel LMF1 Nonsense Mutation in a Patient with Severe Hypertriglyceridemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4584-4590.	3.6	52
202	Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. <i>Atherosclerosis</i> , 2012, 222, 222-228.	0.8	52
203	Site of Insulin Resistance in Type 1 Diabetes: Insulin-Mediated Glucose Disposal <i>in Vivo</i> in Relation to Insulin Binding and Action in Adipocytes <i>in Vitro</i> *. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1984, 59, 1183-1192.	3.6	51
204	Metabolic effects of metformin in patients with impaired glucose tolerance. <i>Diabetic Medicine</i> , 2001, 18, 578-583.	2.3	51
205	The inherent accuracy of <sup>1</sup> H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. <i>Atherosclerosis</i> , 2007, 190, 352-358.	0.8	51
206	OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism. <i>Journal of Molecular Medicine</i> , 2009, 87, 825-835.	3.9	50
207	HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2351-2358.	8.6	50
208	LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. <i>Journal of Lipid Research</i> , 2002, 43, 598-603.	4.2	49
209	TCF7L2 is associated with high serum triacylglycerol and differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. <i>Diabetologia</i> , 2007, 51, 62-69.	6.3	48
210	Reconsideration of hydrophobic lipid distributions in lipoprotein particles. <i>Chemistry and Physics of Lipids</i> , 2008, 155, 57-62.	3.2	48
211	The Contribution of GWAS Loci in Familial Dyslipidemias. <i>PLoS Genetics</i> , 2016, 12, e1006078.	3.5	48
212	Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normolipidemic smoking men: relations with lipid transfer proteins and LCAT activities. <i>Journal of Lipid Research</i> , 1998, 39, 1493-1502.	4.2	48
213	Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia. <i>Atherosclerosis</i> , 1988, 69, 249-255.	0.8	47
214	Short-Term Effects of Prednisone on Serum Lipids and High Density Lipoprotein Subfractions in Normolipidemic Healthy Men *. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 67, 291-299.	3.6	47
215	New Insights into Lipid Metabolism in Non-insulin-dependent Diabetes Mellitus. <i>Annals of Medicine</i> , 1996, 28, 335-340.	3.8	47
216	Insulin resistance is a prominent feature of patients with pancreatogenic diabetes. <i>Metabolism: Clinical and Experimental</i> , 1986, 35, 718-727.	3.4	46

#	ARTICLE	IF	CITATIONS
217	A marathon run increases the susceptibility of LDL to oxidation in vitro and modifies plasma antioxidants. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1999, 276, E1083-E1091.	3.5	46
218	Pathogenesis of dyslipidemia in type 2 diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2001, 109, S180-S188.	1.2	46
219	LDL-cholesterol, HDL-cholesterol or triglycerides – which is the culprit?. <i>Diabetes Research and Clinical Practice</i> , 2003, 61, S19-S26.	2.8	46
220	Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. <i>European Journal of Endocrinology</i> , 2006, 155, 453-460.	3.7	46
221	Lipoprotein Lipase Activity in Adipose Tissue and in Postheparin Plasma in Human Obesity. <i>Acta Medica Scandinavica</i> , 1977, 202, 399-408.	0.0	46
222	Characterizing human adipose tissue lipids by long echo time $^1\text{H}$ -MRS <i>in vivo</i> at 1.5T: validation by gas chromatography. <i>NMR in Biomedicine</i> , 2010, 23, 466-472.	2.8	46
223	High density lipoprotein subfractions, apolipoprotein A-I containing lipoproteins, lipoprotein (a), and cholesteryl ester transfer protein activity in alcoholic women before and after ethanol withdrawal. <i>European Journal of Clinical Investigation</i> , 1993, 23, 406-417.	3.4	44
224	Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, 484-490.	4.0	44
225	Increased augmentation of central blood pressure is associated with increases in carotid intima-media thickness in type 2 diabetic patients. <i>Diabetologia</i> , 2005, 48, 1654-1662.	6.3	44
226	Relationship between lipid profiles and kidney function in patients with type 1 diabetes. <i>Diabetologia</i> , 2007, 51, 12-20.	6.3	44
227	Effect of HDL composition and particle size on the resistance of HDL to the oxidation. <i>Lipids in Health and Disease</i> , 2010, 9, 104.	3.0	44
228	Intestinal alkaline phosphatase at the crossroad of intestinal health and disease – a putative role in type 1 diabetes. <i>Journal of Internal Medicine</i> , 2017, 281, 586-600.	6.0	44
229	Fenofibrate Lowers Plasma Triglycerides and Increases LDL Particle Diameter in Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 627-628.	8.6	43
230	Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 560-568.	4.4	43
231	LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. <i>Journal of Lipid Research</i> , 2002, 43, 598-603.	4.2	43
232	Effects of continuous insulin infusion therapy on lipoprotein surface and core lipid composition in insulin-dependent diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 1991, 40, 445-449.	3.4	42
233	R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. <i>Atherosclerosis</i> , 2004, 177, 127-135.	0.8	42
234	Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial. <i>Cardiovascular Diabetology</i> , 2011, 10, 102.	6.8	42

#	ARTICLE	IF	CITATIONS
235	Coordination of very low-density lipoprotein triglyceride and apolipoprotein B metabolism in humans: Effects of obesity and non-insulin-dependent diabetes mellitus. <i>American Heart Journal</i> , 1987, 113, 522-526.	2.7	41
236	Regulation of Apolipoprotein A-I-Containing Lipoproteins in IDDM. <i>Diabetes</i> , 1993, 42, 1281-1288.	0.6	41
237	Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 271-277.	2.6	41
238	Effect of sulfonylurea therapy on plasma lipids and high-density lipoprotein composition in non-insulin-dependent diabetes mellitus. <i>American Journal of Medicine</i> , 1985, 79, 78-85.	1.5	40
239	No Evidence of Linkage Between Familial Combined Hyperlipidemia and Genes Encoding Lipolytic Enzymes in Finnish Families. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 841-850.	2.4	40
240	Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 589-596.	3.4	39
241	LDL particle size in mildly hypertriglyceridemic subjects: no relation to insulin resistance or diabetes. <i>Atherosclerosis</i> , 1995, 113, 227-236.	0.8	39
242	Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1861-1870.	4.4	39
243	The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease. <i>Molecular Systems Biology</i> , 2020, 16, e9495.	7.2	39
244	ApoA-I Helsinki (Lys 107) Associated With Reduced HDL Cholesterol and LpA-I:A-II Deficiency. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1294-1306.	2.4	38
245	Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. <i>JCI Insight</i> , 2020, 5, .	5.0	38
246	Serum C3 but Not Plasma Acylation-Stimulating Protein Is Elevated in Finnish Patients With Familial Combined Hyperlipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 838-843.	2.4	37
247	A low high density lipoprotein (HDL) level is associated with carotid artery intima-media thickness in asymptomatic members of low HDL families. <i>Atherosclerosis</i> , 2002, 165, 309-316.	0.8	37
248	Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics. <i>Journal of Internal Medicine</i> , 2019, 285, 562-577.	6.0	37
249	A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies. <i>Atherosclerosis</i> , 2003, 168, 131-138.	0.8	36
250	Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. <i>Journal of Lipid Research</i> , 2004, 45, 2303-2309.	4.2	36
251	Lifestyle modification improves risk factors in type 2 diabetes relatives. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, 18-28.	2.8	36
252	1H NMR metabonomics of plasma lipoprotein subclasses: elucidation of metabolic clustering by self-organising maps. <i>NMR in Biomedicine</i> , 2007, 20, 658-672.	2.8	36

#	ARTICLE	IF	CITATIONS
253	Estimation of VLDL, IDL, LDL, HDL <sub>2</sub> , apoA-I, and apoB from the Friedewald inputs—apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes. <i>Annals of Medicine</i> , 2009, 41, 451-461.	3.8	36
254	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. <i>International Journal of Clinical Practice</i> , 2012, 66, 731-740.	1.7	36
255	Effect of Muscular Exercise on Insulin Secretion. <i>Diabetes</i> , 1968, 17, 209-218.	0.6	35
256	Plasma Cholesteryl Ester Transfer Protein and Its Relationship to Plasma Lipoproteins and Apolipoprotein A-I-Containing Lipoproteins in IDDM Patients With Microalbuminuria and Clinical Nephropathy. <i>Diabetes Care</i> , 1994, 17, 412-419.	8.6	35
257	Genomic, Transcriptomic, and Lipidomic Profiling Highlights the Role of Inflammation in Individuals With Low High-density Lipoprotein Cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 847-857.	2.4	35
258	In vitro catabolism of human plasma very low density lipoproteins. <i>Atherosclerosis</i> , 1982, 41, 381-394.	0.8	34
259	Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens. <i>Atherosclerosis</i> , 1996, 122, 153-162.	0.8	34
260	HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. <i>Journal of Lipid Research</i> , 2008, 49, 1246-1253.	4.2	34
261	HDL Subspecies in Young Adult Twins: Heritability and Impact of Overweight. <i>Obesity</i> , 2009, 17, 1208-1214.	3.0	34
262	Reduced IGFBP-1 Is Associated With Thickening of the Carotid Wall in Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 1807-1812.	8.6	33
263	Genetic Variation at the Proprotein Convertase Subtilisin/Kexin Type 5 Gene Modulates High-Density Lipoprotein Cholesterol Levels. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 467-475.	5.1	33
264	Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1165-1170.	8.6	33
265	Delayed clearance of postprandial large TG-rich particles in normolipidemic carriers of LPL Asn291Ser gene variant. <i>Journal of Lipid Research</i> , 1999, 40, 1663-1670.	4.2	33
266	High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy. <i>PLoS ONE</i> , 2011, 6, e23589.	2.5	33
267	A novel polymorphism of apolipoprotein A-IV is the result of an asparagine to serine substitution at residue 127. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1992, 1138, 27-33.	3.8	32
268	Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity. <i>Atherosclerosis</i> , 1993, 102, 79-89.	0.8	32
269	Plasma cholesteryl ester transfer protein activity in non-insulin-dependent diabetic patients with and without coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 1498-1502.	3.4	32
270	Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. <i>European Journal of Endocrinology</i> , 2012, 166, 487-492.	3.7	32



#	ARTICLE	IF	CITATIONS
271	Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes. <i>Journal of Internal Medicine</i> , 2021, 290, 632-645.	6.0	32
272	PRESS echo time behavior of triglyceride resonances at 1.5T: Detecting $\gamma$ -3 fatty acids in adipose tissue in vivo. <i>Journal of Magnetic Resonance</i> , 2009, 201, 39-47.	2.1	31
273	Hepatic lipogenesis and a marker of hepatic lipid oxidation, predict postprandial responses of triglyceride-rich lipoproteins. <i>Obesity</i> , 2014, 22, 1854-1859.	3.0	31
274	Basal and postprandial lipoprotein lipase activity in adipose tissue during caloric restriction and refeeding. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 625-630.	3.4	30
275	Different Acute and Chronic Effects of Acipimox Treatment on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes. <i>Diabetic Medicine</i> , 1993, 10, 950-957.	2.3	30
276	Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects. <i>Atherosclerosis</i> , 1999, 146, 381-390.	0.8	30
277	Fat Distribution, Lipid Accumulation in the Liver, and Exercise Capacity Do Not Explain the Insulin Resistance in Healthy Males with a Family History for Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4232-4238.	3.6	30
278	Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. <i>Atherosclerosis</i> , 2004, 172, 267-272.	0.8	30
279	Nocturnal Hypertriglyceridemia and Hyperinsulinemia Following Moderate Evening Intake of Alcohol. <i>Acta Medica Scandinavica</i> , 1977, 202, 173-177.	0.0	30
280	South African Dyslipidaemia Guideline Consensus Statement. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012, 17, 155-165.	0.2	30
281	Does Familial Hypertriglyceridemia Predispose to NIDDM?. <i>Diabetes Care</i> , 1993, 16, 1494-1501.	8.6	29
282	Determinants of low HDL levels in familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 2003, 44, 1536-1544.	4.2	29
283	A Genome-Wide Screen for Interactions Reveals a New Locus on 4p15 Modifying the Effect of Waist-to-Hip Ratio on Total Cholesterol. <i>PLoS Genetics</i> , 2011, 7, e1002333.	3.5	29
284	Serum complement and familial combined hyperlipidemia. <i>Atherosclerosis</i> , 1997, 129, 271-277.	0.8	28
285	Haplotypes of the ApoA-I/C-III/A-IV Gene Cluster and Familial Combined Hyperlipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1810-1817.	2.4	28
286	Hypertriglyceridemia is associated with pre $\beta$ -HDL concentrations in subjects with familial low HDL. <i>Journal of Lipid Research</i> , 2005, 46, 1643-1651.	4.2	28
287	Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in type 2 diabetes and the metabolic syndrome. <i>Atherosclerosis</i> , 2010, 211, 308-314.	0.8	28
288	Cardiac steatosis in patients with dilated cardiomyopathy. <i>Heart</i> , 2014, 100, 1107-1112.	2.9	28

#	ARTICLE	IF	CITATIONS
289	Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. <i>Scientific Reports</i> , 2018, 8, 14200.	3.3	28
290	Subjects With ApoA-I(Lys <sup>107</sup> ) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With All). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 873-880.	2.4	28
291	Genetic Variation in SULF2 Is Associated with Postprandial Clearance of Triglyceride-Rich Remnant Particles and Triglyceride Levels in Healthy Subjects. <i>PLoS ONE</i> , 2013, 8, e79473.	2.5	28
292	Family histories of Type II diabetes and hypertension predict intima-media thickness in patients with Type I diabetes. <i>Diabetologia</i> , 2002, 45, 711-718.	6.3	27
293	Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL. <i>Journal of Lipid Research</i> , 2007, 48, 1409-1416.	4.2	27
294	Galanin Preproprotein Is Associated With Elevated Plasma Triglycerides. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 147-152.	2.4	27
295	Kinetic studies to investigate lipoprotein metabolism. <i>Journal of Internal Medicine</i> , 2012, 271, 166-173.	6.0	27
296	Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. <i>Atherosclerosis</i> , 2018, 276, 124-130.	0.8	27
297	Effect of Acute Ethanol Load on Postheparin Plasma Lipoprotein Lipase and Hepatic Lipase Activities and Intravenous Fat Tolerance. <i>Hormone and Metabolic Research</i> , 1978, 10, 220-223.	1.5	26
298	Enrichment with apolipoprotein E characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: a preliminary report. <i>Atherosclerosis</i> , 1994, 105, 25-34.	0.8	26
299	Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients. <i>Journal of Internal Medicine</i> , 1995, 238, 429-436.	6.0	26
300	Triglyceride is the major atherogenic lipid in NIDDM. , 1997, 13, 93-98.		26
301	Low HDL cholesterol concentration is associated with increased intima-media thickness independent of arterial stiffness in healthy subjects from families with low HDL cholesterol. <i>European Journal of Clinical Investigation</i> , 2003, 33, 457-463.	3.4	26
302	Associations and interactions between lipid profiles, retinopathy and nephropathy in patients with type 1 diabetes: the FinnDiane Study. <i>Journal of Internal Medicine</i> , 2013, 274, 469-479.	6.0	26
303	Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. <i>Journal of Clinical Lipidology</i> , 2020, 14, 77-87.	1.5	26
304	Heterozygous hepatic lipase deficiency, due to two missense mutations R186H and L334F, in the HL gene. <i>Atherosclerosis</i> , 1997, 128, 165-174.	0.8	25
305	The Asn <sup>291</sup> Ser and Ser <sup>477</sup> Stop mutations of the lipoprotein lipase gene and their significance for lipid metabolism in patients with hypertriglyceridaemia. <i>European Journal of Clinical Investigation</i> , 1997, 27, 928-935.	3.4	25
306	HDL Composition Predicts New-Onset Cardiovascular Disease in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2007, 30, 2706-2707.	8.6	25

#	ARTICLE	IF	CITATIONS
307	Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. <i>Diabetologia</i> , 2015, 58, 2035-2044.	6.3	25
308	Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects. <i>Journal of Internal Medicine</i> , 2020, 288, 422-438.	6.0	25
309	Lipoprotein lipase activity of adipose tissue, skeletal muscle and post-heparin plasma in primary endogenous hypertriglyceridaemia: relation to lipoprotein pattern and to obesity. <i>European Journal of Clinical Investigation</i> , 1982, 12, 433-438.	3.4	24
310	Differences in HDL-cholesterol:apoA-I + apoA-II ratio and apoE phenotype with albuminuric status in Type I diabetic patients. <i>Diabetologia</i> , 2000, 43, 1353-1359.	6.3	24
311	Metabolic syndrome aggravates the increased endothelial activation and low-grade inflammation in subjects with familial low HDL. <i>Annals of Medicine</i> , 2006, 38, 229-238.	3.8	24
312	Different Lipid Variables Predict Incident Coronary Artery Disease in Patients With Type 1 Diabetes With or Without Diabetic Nephropathy: The FinnDiane Study. <i>Diabetes Care</i> , 2014, 37, 2374-2382.	8.6	24
313	Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Tj ETQq1 1 0.784314 rgBT /Overlo 2015, 9, 65-71.	1.5	24
314	Coronary Artery Disease Risk and Lipidomic Profiles Are Similar in Hyperlipidemias With Family History and Population-Ascertained Hyperlipidemias. <i>Journal of the American Heart Association</i> , 2019, 8, e012415.	3.7	24
315	Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. <i>Atherosclerosis</i> , 1997, 129, 249-259.	0.8	23
316	Aggregation of dimyristoylphosphatidylglycerol liposomes by human plasma low density lipoprotein. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1998, 1373, 147-162.	2.6	23
317	Determinants of the severity and extent of coronary artery disease in patients with type-2 diabetes and in nondiabetic subjects. <i>Coronary Artery Disease</i> , 2001, 12, 99-106.	0.7	23
318	A nonsynonymous SNP within PCDH15 is associated with lipid traits in familial combined hyperlipidemia. <i>Human Genetics</i> , 2010, 127, 83-89.	3.8	23
319	The effect of vildagliptin therapy on atherogenic postprandial remnant particles and <sc>LDL</sc> particle size in subjects with Type 2 diabetes. <i>Diabetic Medicine</i> , 2013, 30, 756-757.	2.3	23
320	Effect of parenteral hyperalimentation on serum lipoproteins and on lipoprotein lipase activity of adipose tissue and skeletal muscle. <i>European Journal of Clinical Investigation</i> , 1981, 11, 317-323.	3.4	22
321	Human postheparin plasma hepatic lipase activity against triacylglycerol and phospholipid substrates. <i>Clinica Chimica Acta</i> , 1982, 122, 39-45.	1.1	22
322	Lipoprotein(a) in Type 1 Diabetic Patients with Renal Disease. <i>Diabetic Medicine</i> , 1994, 11, 961-967.	2.3	22
323	A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. <i>Contemporary Clinical Trials</i> , 1997, 18, 93-119.	1.9	22
324	Carotid artery intima-media thickness in Finnish families with familial combined hyperlipidemia. <i>Atherosclerosis</i> , 2002, 162, 171-178.	0.8	22

#	ARTICLE	IF	CITATIONS
325	Locus for quantitative HDL-cholesterol on chromosome 10q in Finnish families with dyslipidemia. <i>Journal of Lipid Research</i> , 2004, 45, 1876-1884.	4.2	22
326	Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profiles. <i>Bioinformatics</i> , 2007, 23, i519-i528.	4.1	22
327	Interrelationships Between the Kinetics of VLDL Subspecies and HDL Catabolism in Abdominal Obesity: A Multicenter Tracer Kinetic Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4281-4290.	3.6	22
328	High-fat meals induce systemic cytokine release without evidence of endotoxemia-mediated cytokine production from circulating monocytes or myeloid dendritic cells. <i>Acta Diabetologica</i> , 2015, 52, 315-322.	2.5	22
329	The Effect of Insulin Delivery Route on Lipoproteins in Type I Diabetic Patients on CAPD. <i>Peritoneal Dialysis International</i> , 1999, 19, 148-153.	2.3	21
330	The ATF6-Met[67]Val Substitution Is Associated With Increased Plasma Cholesterol Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1322-1327.	2.4	21
331	Lipoprotein lipase activity in adipose tissue and skeletal muscle of human diabetics during insulin deprivation and restoration. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1981, 41, 263-268.	1.2	20
332	Effect of insulin treatment on fatty acids of plasma and erythrocyte membrane lipids in type 2 diabetes. <i>Clinica Chimica Acta</i> , 1988, 171, 293-303.	1.1	20
333	Effects of dietary cholesterol on plasma lipoproteins and their subclasses in IDDM patients. <i>Diabetologia</i> , 1998, 41, 193-200.	6.3	20
334	Early alterations in the postprandial VLDL1 apoB-100 and apoB-48 metabolism in men with strong heredity for type 2 diabetes. <i>Journal of Internal Medicine</i> , 2004, 255, 273-279.	6.0	20
335	USF1 gene variants contribute to metabolic traits in men in a longitudinal 32-year follow-up study. <i>Diabetologia</i> , 2008, 51, 464-472.	6.3	20
336	Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2012, 14, 721-731.	2.9	20
337	Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1191-1201.	4.4	20
338	Different effects of continuous oestrogen-progestin and transdermal oestrogen with cyclic progestin regimens on low-density lipoprotein subclasses. <i>European Journal of Clinical Investigation</i> , 1996, 26, 1125-1133.	3.4	19
339	Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. <i>British Journal of Cancer</i> , 2004, 91, 476-481.	6.4	19
340	A male-specific quantitative trait locus on 1p21 controlling human stature. <i>Journal of Medical Genetics</i> , 2005, 42, 932-939.	3.2	19
341	Dietary omega-3 polyunsaturated fatty acid intake is related to a protective high-density lipoprotein subspecies profile independent of genetic effects: A monozygotic twin pair study. <i>Atherosclerosis</i> , 2011, 219, 880-886.	0.8	19
342	Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men. <i>PLoS ONE</i> , 2016, 11, e0145890.	2.5	19

#	ARTICLE	IF	CITATIONS
343	An expanded analysis framework for multivariate GWAS connects inflammatory biomarkers to functional variants and disease. <i>European Journal of Human Genetics</i> , 2021, 29, 309-324.	2.8	19
344	Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypes. <i>Annals of Medicine</i> , 2002, 34, 48-54.	3.8	18
345	Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low high-density lipoprotein cholesterol and features of metabolic syndrome. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1502-1509.	3.4	18
346	Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese men. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 534-542.	2.6	18
347	Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 962-975.	2.4	18
348	Fibrinolytic Proteins and Progression of Coronary Artery Disease in Relation to Gemfibrozil Therapy. <i>Thrombosis and Haemostasis</i> , 2000, 83, 397-403.	3.4	17
349	Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL families. <i>Atherosclerosis</i> , 2000, 153, 373-381.	0.8	17
350	A candidate gene study in low HDL-cholesterol families provides evidence for the involvement of the APOA2 gene and the APOA1C3A4 gene cluster. <i>Atherosclerosis</i> , 2002, 164, 103-111.	0.8	17
351	Is Metabolic Syndrome the Main Threat to Human Health in the Twenty-First Century?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2275-2275.	2.4	17
352	The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes: No relationship between apoA-V and postheparin plasma lipolytic activity. <i>Diabetes Care</i> , 2007, 30, 2083-2085.	8.6	17
353	Insulin resistance as predictor of the angiographic severity and extent of coronary artery disease. <i>Annals of Medicine</i> , 2007, 39, 137-144.	3.8	17
354	Variation in GYS1 Interacts with Exercise and Gender to Predict Cardiovascular Mortality. <i>PLoS ONE</i> , 2007, 2, e285.	2.5	17
355	Patients with type 1 diabetes show signs of vascular dysfunction in response to multiple high-fat meals. <i>Nutrition and Metabolism</i> , 2014, 11, 28.	3.0	17
356	High-resolution population-specific recombination rates and their effect on phasing and genotype imputation. <i>European Journal of Human Genetics</i> , 2021, 29, 615-624.	2.8	17
357	Effect of Pancreas Transplantation on Free Fatty Acid Metabolism in Uremic IDDM Patients. <i>Diabetes</i> , 1996, 45, 354-360.	0.6	16
358	Strategies for the Management of Diabetic Dyslipidaemia. <i>Drugs</i> , 1999, 58, 47-51.	10.9	16
359	Suppression of nocturnal fatty acid concentrations by bedtime carbohydrate supplement in type 2 diabetes: effects on insulin sensitivity, lipids, and glycemic control. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 1108-1114.	4.7	16
360	A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men. <i>Growth Hormone and IGF Research</i> , 2000, 10, 118-126.	1.1	16

#	ARTICLE	IF	CITATIONS
361	Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 274-279.	2.3	16
362	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2014, 35, 1824-1824.	2.2	16
363	USF1 deficiency alleviates inflammation, enhances cholesterol efflux and prevents cholesterol accumulation in macrophages. <i>Lipids in Health and Disease</i> , 2018, 17, 285.	3.0	16
364	Postheparin Plasma Lipase Activities and Plasma Lipoproteins in Newborn Infants. <i>Pediatric Research</i> , 1984, 18, 642-647.	2.3	15
365	Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a). <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2028-2033.	3.6	15
366	Lipoprotein metabolism in subjects with hepatic lipase deficiency. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 520-525.	3.4	15
367	Transgenic Expression and Genetic Variation of Lmf1 Affect LPL Activity in Mice and Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1204-1210.	2.4	15
368	Hyperinsulinism and Dyslipidemias as Coronary Heart Disease Risk Factors in NIDDM. <i>Advances in Experimental Medicine and Biology</i> , 1993, 334, 295-301.	1.6	15
369	Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. <i>Diabetologia</i> , 1996, 39, 993-996.	6.3	14
370	In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107 $\rightarrow$ 0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency. <i>Atherosclerosis</i> , 1997, 128, 213-222.	0.8	14
371	ApoE Polymorphism Is Associated With C-Reactive Protein in Low-HDL Family Members and in Normolipidemic Subjects. <i>Mediators of Inflammation</i> , 2006, 2006, 1-5.	3.0	14
372	Postheparin Plasma Lipoprotein and Hepatic Lipase Activities in Hyperinsulinemic Infants of Diabetic Mothers and in Large-for-Date Infants at Birth. <i>Pediatric Research</i> , 1986, 20, 623-627.	2.3	13
373	C3, hormone-sensitive lipase, and peroxisome proliferator-activated receptor [ $\gamma$ ] expression in adipose tissue of familial combined hyperlipidemia patients. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 664-670.	3.4	13
374	Functional Variant Disrupts Insulin Induction of USF1. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 522-529.	5.1	13
375	Reviewing statin therapy in diabetes – Towards the best practise. <i>Primary Care Diabetes</i> , 2010, 4, 9-15.	1.8	13
376	Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: A FIELD substudy. <i>Atherosclerosis</i> , 2011, 219, 259-265.	0.8	13
377	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses. <i>Journal of Clinical Lipidology</i> , 2019, 13, 979-988.e10.	1.5	13
378	Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. <i>Diabetologia</i> , 1996, 39, 453-461.	6.3	13

#	ARTICLE	IF	CITATIONS
379	EFFECT OF DIPHENYLHYDANTOIN ON PLASMA-INSULIN IN INSULINOMA. <i>Lancet, The</i> , 1973, 301, 604-605.	13.7	12
380	Role of hepatic endothelial lipase in the metabolism of plasma HDL2. <i>Atherosclerosis</i> , 1982, 44, 237-240.	0.8	12
381	Effect of insulin treatment on serum lipoprotein(a) in non-insulin-dependent diabetes. <i>European Journal of Clinical Investigation</i> , 1995, 25, 194-200.	3.4	12
382	Oestrogen replacement therapy and coronary heart disease. <i>Annals of Medicine</i> , 1998, 30, 443-451.	3.8	12
383	Genetic influences contributing to LDL particle size in familial combined hyperlipidaemia. <i>European Journal of Human Genetics</i> , 2002, 10, 547-552.	2.8	12
384	Metabolomic analysis of polar metabolites in lipoprotein fractions identifies lipoprotein-specific metabolic profiles and their association with insulin resistance. <i>Molecular BioSystems</i> , 2012, 8, 2559.	2.9	12
385	Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. <i>Diabetologia</i> , 1995, 38, 363-369.	6.3	12
386	Effects of interferon alpha on insulin binding and glucose transport in human adipocytes. <i>European Journal of Clinical Investigation</i> , 1992, 22, 292-299.	3.4	11
387	Criteria for Metabolic Control and Intervention in Diabetes. <i>Diabetes</i> , 1996, 45, S120-S122.	0.6	11
388	Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans. <i>Frontiers in Physiology</i> , 2015, 6, 342.	2.8	11
389	Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. <i>Clinical Chemistry</i> , 2017, 63, 1261-1270.	3.2	11
390	Metabolic syndrome associates with left atrial dysfunction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 727-734.	2.6	11
391	Relationship between de novo lipogenesis and serum sex hormone binding globulin in humans. <i>Clinical Endocrinology</i> , 2021, 95, 101-106.	2.4	11
392	Changes of lipolytic enzymes cluster with insulin resistance syndrome. <i>Diabetologia</i> , 1995, 38, 344-350.	6.3	11
393	No Evidence of Amyloidosis in Type I Diabetics Treated with Continuous Subcutaneous Insulin Infusion. <i>Diabetes</i> , 1983, 32, 88-90.	0.6	10
394	One-year response to evening insulin therapy in non-insulin-dependent diabetes. <i>Journal of Internal Medicine</i> , 1992, 231, 253-260.	6.0	10
395	No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 376-381.	4.0	10
396	Optimization of N -methyl-N -[tert -butyldimethylsilyl]trifluoroacetamide as a derivatization agent for determining isotopic enrichment of glycerol in very-low density lipoproteins. <i>Rapid Communications in Mass Spectrometry</i> , 2010, 24, 586-592.	1.5	10

#	ARTICLE	IF	CITATIONS
397	Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia. <i>BMC Endocrine Disorders</i> , 2014, 14, 90.	2.2	10
398	Apolipoprotein C-II predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria. <i>Journal of Internal Medicine</i> , 2022, 291, 338-349.	6.0	10
399	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1663-1674.	1.8	9
400	Early Response of Plasma Insulin to Small Doses of Intravenous Glucose: Effect of Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1974, 39, 418-424.	3.6	8
401	Changes in biological activity and immunoreactive mass of lipoprotein lipase in congenital nephrosis: relationship to hypertriglyceridaemia. <i>European Journal of Clinical Investigation</i> , 1993, 23, 368-374.	3.4	8
402	Associations between HDL oxidation and paraoxonase-1 and paraoxonase-1 gene polymorphisms in families affected by familial combined hyperlipidemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 81-87.	2.6	8
403	Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain. <i>Annals of Medicine</i> , 2013, 45, 322-327.	3.8	8
404	Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. <i>Scientific Reports</i> , 2020, 10, 11561.	3.3	8
405	Postheparin Plasma Lipoprotein and Hepatic Lipase Activities in Hyperinsulinemic Infants of Diabetic Mothers and in Large-for-Date Infants at Birth. <i>Pediatric Research</i> , 1986, 20, 527-531.	2.3	7
406	Electrocardiographic changes associated with insulin resistance. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 315-320.	2.6	7
407	Measuring short-term liver metabolism non-invasively: postprandial and post-exercise 1H and 31P MR spectroscopy. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2015, 28, 57-66.	2.0	7
408	Acquired liver fat is a key determinant of serum lipid alterations in healthy monozygotic twins. <i>Obesity</i> , 2013, 21, 1815-1822.	3.0	6
409	Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family. <i>Atherosclerosis</i> , 2017, 264, 58-66.	0.8	6
410	Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1388-1396.	4.4	6
411	Metabolism of Triglyceride-Rich Lipoproteins. <i>Handbook of Experimental Pharmacology</i> , 2021, , 133-156.	1.8	6
412	Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 509-512.	2.6	5
413	Postprandial triglyceride-rich lipoproteins in insulin resistance and Type 2 diabetes. <i>Future Lipidology</i> , 2008, 3, 531-543.	0.5	5
414	Biomarkers and prediction of myocardial triglyceride content in non-diabetic men. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 134-140.	2.6	5



#	ARTICLE	IF	CITATIONS
415	Effects of <i>PNPLA3</i> I148M on hepatic lipid and very-low-density lipoprotein metabolism in humans. <i>Journal of Internal Medicine</i> , 2022, 291, 218-223.	6.0	5
416	Comparison of Acute Daytime and Nocturnal Insulinization on Diurnal Glucose Homeostasis in NIDDM. <i>Diabetes Care</i> , 1994, 17, 805-809.	8.6	4
417	Genetic prediction of the metabolic syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2008, 2, 245-252.	3.6	4
418	A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model. <i>BMC Systems Biology</i> , 2013, 7, 8.	3.0	4
419	Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models. <i>PLoS ONE</i> , 2015, 10, e0138538.	2.5	4
420	ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1398-1406.	3.6	4
421	Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2723-2725.	3.6	4
422	Lipoproteins and Apoproteins in Diabetes. <i>Frontiers in Diabetes</i> , 1993, 12, 122-134.	0.4	3
423	EDITORIAL COMMENT: New insights into the regulation of lipoprotein metabolism: studies in prokaryotes, eukaryotes, rodents, pigs, and people. <i>Current Opinion in Lipidology</i> , 1997, 8, 127-130.	2.7	3
424	Postprandial responses of plasma lipids and lipoproteins in subjects with apoA-I(Lys107→O). <i>Atherosclerosis</i> , 1998, 137, 37-47.	0.8	3
425	INSULIN DEFICIENCY ASSOCIATED WITH HYPOGLYCEMIA AND GOOD GLUCOSE TOLERANCE IN HYPOPITUITARISM. <i>Acta Medica Scandinavica</i> , 1974, 195, 435-439.	0.0	3
426	Introduction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 377-378.	2.6	3
427	South African Dyslipidaemia Guideline Consensus Statement. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2013, 55, 9-18.	0.6	3
428	Elevated adipose tissue lipoprotein lipase activity in craniopharyngioma patients. <i>Metabolism: Clinical and Experimental</i> , 1988, 37, 418-421.	3.4	2
429	The FIELD study – Authors' reply. <i>Lancet</i> , 2006, 367, 1142-1143.	13.7	2
430	ADAGIO-Lipids Gives Promises but Faces the Setbacks. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 339-340.	2.4	2
431	Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS). <i>Atherosclerosis</i> , 2014, 233, 508-509.	0.8	2
432	Postmenopausal hormone replacement therapy and plasma lipoproteins. <i>Journal of Internal Medicine</i> , 1995, 238, 385-387.	6.0	1

#	ARTICLE	IF	CITATIONS
433	Development and Evaluation of an ELISA Method for the Determination of Lipoprotein Lipase Mass Concentration – Comparison with a Commercial, One-Step Enzyme Immunoassay. <i>Clinical Chemistry and Laboratory Medicine</i> , 1996, 34, 547-53.	2.3	1
434	4.P.213 Asn291Ser mutation in LPL gene does not cause fat intolerance in normotriglyceridemic carriers. <i>Atherosclerosis</i> , 1997, 134, 340.	0.8	1
435	Genetic variation in the amino-terminal part of apolipoprotein B: studies in hyperlipidemic patients. <i>Atherosclerosis</i> , 1998, 138, 367-374.	0.8	1
436	IGF Binding Protein-1 and Carotid Intima-Media Thickness in Type 2 Diabetes: Response to Conti et al.. <i>Diabetes Care</i> , 2003, 26, 1654-1655.	8.6	1
437	Abnormalities of triglyceride rich lipoproteins (TRLs) in type 2 diabetes and insulin resistance. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2010, 22, 36-38.	0.8	1
438	A higher glycemic response to oral glucose is associated with higher plasma apolipoprotein C3 independently of BMI in healthy twins. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 459-466.	2.6	1
439	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 18708.	3.3	1
440	LDL subclasses in IDDM patients: relation to diabetic nephropathy. <i>Diabetologia</i> , 1994, 37, 681-688.	6.3	1
441	23-LB: Lipoprotein Subfractions Are Associated with Diabetic Cardiovascular Disease and Death among 9,795 Patients in the FIELD Trial. <i>Diabetes</i> , 2019, 68, .	0.6	1
442	Mechanisms behind the abnormalities of plasma lipids and lipoproteins in noninsulin-dependent diabetes. <i>The Journal of Diabetic Complications</i> , 1990, 4, 49-52.	0.2	0
443	Seventy Years of Insulin: Where are We Now?. <i>Annals of Medicine</i> , 1992, 24, 231-232.	3.8	0
444	Postprandial lipemia and lipoprotein lipase. <i>Atherosclerosis</i> , 1994, 109, 339-340.	0.8	0
445	4.W23.5 Is insulin regulation of VLDL production defective in insulin resistance?. <i>Atherosclerosis</i> , 1997, 134, 292.	0.8	0
446	1.P.128 LDL subclasses in familial combined hyperlipidemia (FCHL). <i>Atherosclerosis</i> , 1997, 134, 43.	0.8	0
447	1.P.131 The occurrence of small dense low density lipoprotein particles in familial combined hyperlipidemia. <i>Atherosclerosis</i> , 1997, 134, 44.	0.8	0
448	1.P.260 Candidate gene analysis in familial combined hyperlipidemia. <i>Atherosclerosis</i> , 1997, 134, 71.	0.8	0
449	3.P.80 The susceptibility of LDL to oxidation is determined by LDL particle size in familial combined hyperlipidemia (FCHL) subjects. <i>Atherosclerosis</i> , 1997, 134, 215.	0.8	0
450	Broader metabolic control in diabetes management. <i>Diabetes/metabolism Reviews</i> , 1998, 14, S39-S43.	0.3	0

#	ARTICLE	IF	CITATIONS
451	Dyslipidemia in insulin resistance: A silent villain?. <i>Atherosclerosis</i> , 1999, 144, 12-13.	0.8	0
452	Endothelial dysfunction and insulin resistance in men with small LDL particles. <i>Atherosclerosis</i> , 1999, 144, 58-59.	0.8	0
453	Delayed clearance of postprandial large VLDL particles in normolipidemic carriers of LPL Asn291Ser mutation. <i>Atherosclerosis</i> , 1999, 144, 89.	0.8	0
454	Isolated low HDL-cholesterol syndrome in finnish families with premature CAD. <i>Atherosclerosis</i> , 1999, 144, 106.	0.8	0
455	New aspects to the pathophysiology of diabetic dyslipidemia. <i>Atherosclerosis</i> , 1999, 144, 153-154.	0.8	0
456	A Genome-wide scan for low HDL-Cholesterol in genetically isolated finnish families with premature coronary heart disease. <i>Atherosclerosis</i> , 2000, 151, 236.	0.8	0
457	LB-PO-860 COMPREHENSIVE METABOLOMIC CHARACTERISATION OF LIPOPROTEIN FRACTIONS REVEALS DIFFERENTIAL LIPOPROTEIN-SPECIFIC REGULATION OF XENOBIOTIC AND PRO-INFLAMMATORY METABOLITES IN PATIENTS WITH METABOLIC SYNDROME. <i>Atherosclerosis Supplements</i> , 2007, 8, 230-231.	1.2	0
458	The role of PPAR- $\alpha$ agonists in the prevention of CVD in diabetes. <i>Current Diabetes Reports</i> , 2007, 7, 83-85.	4.2	0
459	ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition and increased susceptibility for sphingomyelinase. <i>Chemistry and Physics of Lipids</i> , 2008, 154, S13.	3.2	0
460	MS23 TARGETING ONLY HIGH LDL-CHOLESTEROL DOES NOT ELIMINATE RESIDUAL CARDIOVASCULAR RISK. <i>Atherosclerosis Supplements</i> , 2010, 11, 114.	1.2	0
461	MS49 THE HELSINKI FIELD SUBSTUDY: EFFECTS OF FENOFIBRATE AND HOMOCYSTEINE ON IN VITRO CHOLESTEROL EFFLUX POTENTIAL OF HDL AND PLASMA. <i>Atherosclerosis Supplements</i> , 2010, 11, 120.	1.2	0
462	839 SERUM APOLIPOPROTEIN CIII LEVELS DECLINE AFTER WEIGHT LOSS INDUCED IMPROVEMENT IN HEPATIC STEATOSIS. <i>Journal of Hepatology</i> , 2011, 54, S335-S336.	3.7	0
463	Response Letter to D. Singh&Franco et al.. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 1054-1055.	4.4	0
464	1334 CORRELATION OF HUMAN LIVER PPAR GENE EXPRESSION WITH HISTOLOGICAL SEVERITY OF NASH AND ASSOCIATED METABOLIC DERANGEMENTS: RATIONALE FOR TARGETED THERAPY. <i>Journal of Hepatology</i> , 2013, 58, S538.	3.7	0
465	POLYGENIC HYPERLIPIDEMIAS AND CORONARY ARTERY DISEASE RISK. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1690.	2.8	0
466	Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate " Authorsâ€™ response. <i>Journal of Internal Medicine</i> , 2020, 287, 118-118.	6.0	0
467	Evidence of linkage in familial combined hyperlipidemia to chromosome 1q21-q23. , 2000, , 56-58.		0
468	Lipolytic Enzymes and HDL: Influence of Drugs and Hormones. <i>Proceedings in Life Sciences</i> , 1987, , 231-235.	0.5	0

#	ARTICLE	IF	CITATIONS
469	Hypolipoproteinemia and Lipoprotein Lipase Deficiency. , 1990, , 381-394.		0
470	Factors Influencing the Altered Lipoprotein System in Hypertriglyceridemia. Medical Science Symposia Series, 1993, , 467-475.	0.0	0
471	Dyslipidemia in Niddm: New Insights. Medical Science Symposia Series, 1995, , 165-172.	0.0	0
472	Gemfibrozil Increases Plasma Levels of Cholesterylester Transfer Protein (Cetp), But Lowers Cholesterylester Transfer in Hypertriglyceridemic Subjects. Medical Science Symposia Series, 1996, , 557-565.	0.0	0
473	Lipid metabolism: new approaches to old problems. Current Opinion in Lipidology, 1998, 9, 185-187.	2.7	0
474	41-LB: Lipoprotein Subfractions Are Associated with Diabetic Microvascular Disease among 9,795 Patients in the FIELD Trial. Diabetes, 2019, 68, 41-LB.	0.6	0
475	22-LB: Baseline and Short-Term Change in Plasma Uric Acid on Fenofibrate Predict Cardiovascular Risk: A Post Hoc Analysis of FIELD. Diabetes, 2019, 68, 22-LB.	0.6	0